BioRestorative Therapies Announces Activation Of Northwell Health In The Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced the activation of Northwell Health in the company's Phase 2 clinical trial targeting chronic lumbar disc disease. This activation allows for patients in New York to participate in the BRTX-100 trial. The company's lead clinical candidate, BRTX-100, is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow and limited oxygen supply. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100.
September 08, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioRestorative Therapies' activation of Northwell Health in its Phase 2 clinical trial could potentially increase the patient pool and accelerate the trial process. This could lead to faster results and potential FDA approval, which would be positive for the company's stock.
The activation of Northwell Health in BioRestorative's Phase 2 clinical trial means that the trial can now recruit patients from New York, potentially increasing the patient pool and accelerating the trial process. Faster trial results could lead to quicker FDA approval, which would be a positive development for the company and could boost its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100